Viewing Study NCT04009733


Ignite Creation Date: 2025-12-25 @ 2:59 AM
Ignite Modification Date: 2026-01-01 @ 4:37 AM
Study NCT ID: NCT04009733
Status: COMPLETED
Last Update Posted: 2025-09-04
First Post: 2019-06-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
Sponsor: Hospices Civils de Lyon
Organization:

Study Overview

Official Title: Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
Status: COMPLETED
Status Verified Date: 2023-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: miROI
Brief Summary: Osteogenesis Imperfecta (OI) is a heterogeneous group of rare connective tissue hereditary diseases responsible for fragility and bone deformity. OI is caused by an autosomal dominant mutation of COL1A1 or COL1A2, encoding α1 and α2 of the collagen, regardless of their phenotypic severity (1 to 5 OI type).

This observation suggests the existence of a undetermined mechanism that may be found in epigenetic regulation, including particularly micro Ribonucleic Acids (miRs).

Indeed, these small non-coding miRs are involved in the regulation of major steps of cellular processes in different pathologies, especially in bone disease.

Currently, no study can provide a satisfactory answer.

This is an etiologic study to reveal the correlation between micro-RNAs (miR) expression and the type I or III of the Osteogenesis Imperfecta (OI).

The aim of this study is therefore to identify miRs significantly associated with the severity of OI.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2019-A00521-56 OTHER ID-RCB View